I reached my goal weight — now what?

You did it. The number on the scale matches the goal you set — maybe months ago, maybe years ago. And then comes the question that nobody quite prepares you for: now what? The drug companies spent billions advertising how much weight you could lose. The conversation about what happens at the finish line is considerably quieter.

The trial data shows what actually happens when people reach their target weight — both those who stopped medication and those who stayed on it. The short answer is that stopping usually means regaining. But "usually" doesn't mean "always," and the options available in 2026 are meaningfully different from what they were even a year ago. There are now more paths than just "stay on forever or quit cold turkey."

What follows is the evidence on regain, the three main paths forward, and what lifestyle factors make a real difference — so you can have a real conversation with your doctor about what comes next.

What the regain data actually says

The SURMOUNT-4 trial is the most detailed look at what happens after stopping Zepbound (tirzepatide). Participants spent 36 weeks losing weight on the drug, then were randomised to either continue or switch to placebo. Over the following 52 weeks, those who stopped regained an average of 14% of their body weight. Those who continued lost an additional 5.5%. Only 16.6% of the people who stopped managed to maintain 80% or more of their total weight loss. That means roughly five out of six people who stopped regained a substantial amount.

The picture for Wegovy (semaglutide) is similarly striking. In the STEP 1 follow-up, participants who stopped semaglutide after the trial ended regained approximately two-thirds of the weight they had lost — within a single year. Compare that to STEP 5, the two-year continuation trial, where people who stayed on semaglutide maintained a 15.2% reduction in body weight. The drug kept working for the full two years. The maintenance benefit wasn't eroding; it was stable.

Regain after stopping is not a failure of willpower or motivation. These medications work by suppressing appetite hormones — GLP-1, GIP — that regulate hunger and satiety at a neurological level. When the medication is withdrawn, those hormones return to their pre-treatment levels, often within weeks. The hunger comes back. The cravings return. It's the same biological mechanism as blood pressure rising again when someone stops antihypertensives, or blood glucose climbing when a diabetic stops insulin. The body isn't broken — it's just no longer being managed. That framing matters, because it changes what "now what" actually means.

Three paths forward

Most people who reach their goal weight face a decision about what to do next, and it usually comes down to one of three approaches. The right one depends on cost, side effects, lifestyle, and what your doctor recommends. Here's what the evidence shows for each path.

Path 1: Stay on at a lower dose

Many clinicians work with patients to find the lowest dose that maintains their weight, rather than keeping them on a maximum therapeutic dose indefinitely. In practice, this means stepping down — from 15mg tirzepatide to 10mg or 7.5mg, for example, or from 2.4mg semaglutide to 1.7mg. The formal clinical trial data on specific maintenance doses is limited, but dose reduction is standard practice in clinics that manage long-term treatment.

You're past the active weight loss phase; you don't need the maximum appetite suppression you needed at the beginning. A lower dose means fewer gastrointestinal side effects for most people, and it means lower cost — though the injection cost remains significant even at lower doses. The key advantage is that you keep the hormonal suppression working. The biology that caused regain in the trial participants who stopped doesn't apply if you haven't stopped.

Path 2: Switch from injection to a cheaper pill

This is the option that has changed most in 2026. The ATTAIN-MAINTAIN trial specifically evaluated whether people could switch from an injectable GLP-1 — Wegovy or Zepbound — to oral Foundayo (orforglipron) for maintenance. The average weight difference between people who made the switch and those who stayed on injections was less than 1kg. Not 10kg. Not 5kg. Less than 1kg.

The cost difference is dramatic. Injectable GLP-1s currently run $650–$1,350 per month in the US, depending on the drug and insurance situation. Foundayo launched at $349 per month, with widespread availability at $149 per month through various programmes. Oral Wegovy is in a similar range. The long-term maths changes completely when maintenance costs $149 a month rather than $1,000 a month.

Before this trial, "staying on medication indefinitely" was a financial commitment that made it an unrealistic option for a large proportion of people. The injection-to-pill switch makes lifelong treatment accessible for millions more people. That's a structural change in how the maintenance conversation should be framed.

Path 3: Stop and manage with lifestyle

If someone stops medication because of cost, side effects, personal preference, or because a doctor recommends it, the picture from the trials is that most people — roughly 83%, based on the SURMOUNT-4 data — regain significant weight within a year.

The roughly 17% who do maintain most of their weight loss after stopping are not simply the people with more willpower. The evidence points to specific factors: people who built consistent resistance training habits during their treatment period, and people who significantly increased their protein intake. These lifestyle behaviours work through real metabolic mechanisms that partially offset the hormonal changes that come with stopping medication. They're not a substitute for the drug's effects, but they are the best tools available for the people who do stop.

What actually helps with maintenance

Whether you continue medication or not, two lifestyle factors come up consistently in the maintenance research as the strongest predictors of sustained weight control. The mechanism behind each one explains why they matter — and why most other popular advice for weight maintenance is less reliably effective.

Resistance training — lifting weights, bodyweight exercises, resistance bands — works primarily through its effect on muscle mass. When people lose weight rapidly, as happens on GLP-1 medications, they lose both fat and lean mass. Muscle loss lowers resting metabolic rate, which means the body burns fewer calories at rest. This creates a physiological backdrop that makes weight regain more likely regardless of what you eat. Regular resistance training during and after weight loss preserves lean mass, keeps resting metabolic rate higher, and gives the body a more favourable body composition to maintain. It's the single most impactful lifestyle factor in the maintenance evidence base.

Protein intake is the second major factor. A target of 1.2–1.6g of protein per kg of body weight per day is cited across the research literature for weight maintenance. The mechanisms are multiple: protein supports muscle preservation when combined with resistance training; it promotes satiety more effectively than carbohydrates or fat; and it has a higher thermic effect, meaning the body expends more energy processing protein than other macronutrients. For a 80kg person, 1.2–1.6g/kg means roughly 96–128g of protein per day — achievable through diet but higher than most people currently consume.

These lifestyle tools are not replacements for the hormonal effects of GLP-1 drugs. The trial data is consistent: the medication's impact on appetite regulation is too powerful to replicate through diet and exercise alone for most people. But for the minority who do maintain after stopping, and as a complement to continued treatment for everyone else, resistance training and high protein intake appear to be the difference between maintaining 80% of a weight loss and maintaining 20% of it.